Printer Friendly

Encysive Announces Its Majority-Owned Subsidiary, Revotar Biopharmaceuticals AG, Reported Positive Data in Asthma with Small Molecule Selectin Antagonist.

Business Editors/Health/Medical Writers


Encysive Pharmaceuticals (Nasdaq:ENCY) today announced that its majority-owned German affiliate, Revotar Biopharmaceuticals AG, reported positive results with bimosiamose in a 12 patient, double-blind, cross-over, allergen challenge study in mild asthmatics. The results demonstrated for the first time that a small molecule selectin antagonist can decrease Late Asthmatic Response (LAR), a standard measure of asthma, in patients following allergen challenge.

The study with bimosiamose achieved its primary endpoint of LAR decline vs. maximum FEV1 baseline values (p=0.05, Wilcoxon Signed Rank Test). This endpoint is recommended by the American Thoracic Society for asthma studies of this type. Bimosiamose was also shown to be well tolerated.

"These intriguing results point to a potentially important new approach in the treatment of asthma," said Bruce D. Given, M.D., president and CEO of Encysive Pharmaceuticals Inc. "We view these findings as proof-of-concept that, taken together with previous pilot study results in psoriasis, support additional work in asthma and other diseases associated with inflammation."

Bimosiamose is a pan-selectin antagonist under development by Revotar. In addition to asthma, the company is evaluating bimosiamose in psoriasis and atopic dermatitis. For a complete copy of the Revotar announcement please visit the Revotar Web site at

About Revotar Biopharmaceuticals AG

Revotar Biopharmaceuticals AG is a privately held German company, majority owned by Encysive Pharmaceuticals. The other investors are bmp AG and Medipoint Venture Fonds GmbH, both located in Berlin, Germany. Revotar is located in Hennigsdorf, State of Brandenburg, Germany, and is committed to the discovery and development of small molecule drugs to treat inflammation. Revotar Biopharmaceuticals AG owns proprietary rights to the development of small molecules against Macrophage Migration Inhibitor (MIF), and the Junctional Adhesion Molecule-1 (JAM-1) and its interaction with LFA-1. Its lead compound bimosiamose (small molecule selectin antagonist) is also being developed in Phase II clinical trials for the topical treatment of psoriasis and atopic dermatitis. Other indications such as COPD, inflammatory bowel disease, reperfusion injury, sepsis, rheumatoid arthritis and transplantation may also become promising targets for selectin antagonists. To learn more about Revotar Biopharmaceuticals AG please visit their Web site:

About Encysive Pharmaceuticals

Encysive Pharmaceuticals, a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for our expertise in small molecule drug development and vascular biology. Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III development of the endothelin antagonist, sitaxsentan, for pulmonary arterial hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in Phase II development with the selectin antagonist bimosiamose in asthma, psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other research and development programs ongoing for a range of cardiovascular and inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit our Web site:

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are timing and cost of our clinical trials, attainment of research and clinical goals and milestones of product candidates, attainment of required government approvals, sales levels of our products and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Encysive Pharmaceuticals, including as Texas Biotechnology Corporation, has filed with the Securities and Exchange Commission. The company undertakes no duty to update of revise these forward-looking statements.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUGE
Date:Aug 5, 2003
Previous Adds Instant Guaranteed Prices for Corporate Charters.
Next Article:Gateway Announces Quarterly Filings.

Related Articles
Acute effects of antileukotrienes on sinonasal polyposis and sinusitis.
SUR4 Effects of estrogen and/or progesterone exposure on interleukin-1 beta induced expression of Vcam-1, Icam-1, Pecam, and E-selectin by human...
Highlights from the annual scientific assembly: patient-centered approaches to asthma management: strategies for treatment and management of asthma....
Biologic effects induced in vitro by P[M.sub.10] from three different zones of Mexico City. (Research Articles).
Sugar-protein link joins embryo to Mom. (Getting Attached).
FDA Advisory Committee Unanimously Recommends Approval of Xolair; Potential First Biologic Treatment for Allergic Asthma Targets Underlying Cause of...
FDA Approves Xolair, Biotechnology Breakthrough for Asthma; First Humanized Antibody for Asthma Targets IgE, an Underlying Cause of the Disease.
Encysive Pharmaceuticals Reports Third Quarter 2003 Results; Conference Call Scheduled for Today at 4:30 p.m. Eastern.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters